OLAMART-150

Advanced PARP Inhibitor for Ovarian, Breast, Pancreatic & Prostate Cancer

OLAMART-150 is a prescription-based targeted anticancer medicine containing Olaparib 150mg, a PARP (Poly ADP-Ribose Polymerase) inhibitor used for the treatment of BRCA-mutated and homologous recombination repair (HRR)-deficient cancers. It is indicated for selected patients with ovarian cancer, breast cancer, pancreatic cancer, and metastatic castration-resistant prostate cancer (mCRPC), as determined by genetic testing and clinical evaluation.

OLAMART-150 represents an important advancement in precision oncology by specifically targeting cancer cells that have defects in DNA repair mechanisms. By inhibiting the PARP enzyme, the medicine prevents cancer cells from repairing DNA damage, leading to cancer cell death while helping preserve healthy cells. It is prescribed by oncology specialists as part of personalized cancer treatment plans.

Key Benefits of OLAMART-150

• Contains Olaparib 150mg, an advanced PARP inhibitor
• Used in the treatment of BRCA-mutated ovarian cancer
• Effective in HER2-negative BRCA-mutated breast cancer
• Indicated for selected pancreatic cancer patients
• Used in metastatic castration-resistant prostate cancer (mCRPC)
• Helps prevent cancer cells from repairing damaged DNA
• Supports personalized targeted cancer therapy
• Convenient oral tablet formulation
• Used under the supervision of a qualified oncologist

Uses of OLAMART-150

OLAMART-150 may be prescribed for:

• Advanced ovarian cancer
• Fallopian tube cancer
• Primary peritoneal cancer
• HER2-negative BRCA-mutated breast cancer
• BRCA-mutated pancreatic cancer
• Metastatic castration-resistant prostate cancer (mCRPC)
• Maintenance therapy following response to platinum-based chemotherapy (as advised by an oncologist)

Why Choose OLAMART-150?

OLAMART-150 offers a precision medicine approach to cancer treatment by targeting tumors with specific genetic mutations. Its clinically proven mechanism helps delay disease progression, improve progression-free survival, and support long-term cancer management. It is widely used in modern oncology for patients who are eligible for targeted PARP inhibitor therapy.

Important Safety Information

• Prescription-only anticancer medicine.
• Use only under the supervision of a qualified oncologist.
• Regular blood tests and monitoring are recommended during treatment.
• Inform your doctor about kidney disease, liver disease, pregnancy, breastfeeding, or any ongoing medications before starting therapy.
• Do not self-medicate or change the prescribed dosage.
• Keep out of reach of children.